Vapotherm Stock Forecast, Price & News

Vapotherm's stock was trading at $7.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VAPO stock has increased by 264.1% and is now trading at $28.36.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vapotherm in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vapotherm.

Vapotherm is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Vapotherm.

Vapotherm Inc (NYSE:VAPO) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.35) EPS for the quarter, beating the Zacks' consensus estimate of ($0.37) by $0.02. The firm had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.45 million. Vapotherm had a negative net margin of 60.31% and a negative return on equity of 62.96%. The company's revenue for the quarter was up 193.3% on a year-over-year basis.
View Vapotherm's earnings history.

Vapotherm updated its third quarter 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $24-28 million, compared to the consensus revenue estimate of $18.65 million.

3 brokers have issued 1 year price targets for Vapotherm's shares. Their forecasts range from $53.00 to $54.00. On average, they expect Vapotherm's stock price to reach $53.50 in the next twelve months. This suggests a possible upside of 88.6% from the stock's current price.
View analysts' price targets for Vapotherm.

Vapotherm saw a decline in short interest in August. As of August 31st, there was short interest totaling 1,850,000 shares, a decline of 11.5% from the August 15th total of 2,090,000 shares. Based on an average trading volume of 740,000 shares, the short-interest ratio is presently 2.5 days. Currently, 11.4% of the shares of the stock are short sold.
View Vapotherm's Short Interest.

Some companies that are related to Vapotherm include Inovio Pharmaceuticals (INO), NuVasive (NUVA), Shockwave Medical (SWAV), Silk Road Medical (SILK), Merit Medical Systems (MMSI), Glaukos (GKOS), Cantel Medical (CMD), AtriCure (ATRC), Axonics Modulation Technologies (AXNX), Cardiovascular Systems (CSII), Atrion (ATRI), Luminex (LMNX), Cerus (CERS), GenMark Diagnostics (GNMK) and OraSure Technologies (OSUR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vapotherm investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Pfizer (PFE), Micron Technology (MU), Square (SQ), Teladoc Health (TDOC), Taiwan Semiconductor Mfg. (TSM), Gilead Sciences (GILD) and Ibio (IBIO).

(VAPO) raised $60 million in an IPO on Wednesday, November 14th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Vapotherm trades on the New York Stock Exchange (NYSE) under the ticker symbol "VAPO."

Vapotherm's stock is owned by many different retail and institutional investors. Top institutional shareholders include Parian Global Management LP (6.63%), Perceptive Advisors LLC (5.24%), Driehaus Capital Management LLC (2.99%), Federated Hermes Inc. (2.33%), Deerfield Management Company L.P. Series C (2.02%) and Goldman Sachs Group Inc. (0.95%). Company insiders that own Vapotherm stock include Anthony L Arnerich, Craig B Reynolds, Elizabeth H Weatherman, Gregoire Ramade, Healthcare Holding BV Gilde, James W Liken, John Landry, Joseph Army, Marina Hahn, Michael Mcqueen, Prescott General Partners Llc and Thomas W Smith.
View institutional ownership trends for Vapotherm.

VAPO stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Perceptive Advisors LLC, Deerfield Management Company L.P. Series C, Spouting Rock Asset Management LLC, Cubist Systematic Strategies LLC, and Taylor Frigon Capital Management LLC. Company insiders that have sold Vapotherm company stock in the last year include Craig B Reynolds, Gregoire Ramade, and Marina Hahn.
View insider buying and selling activity for Vapotherm.

VAPO stock was bought by a variety of institutional investors in the last quarter, including Parian Global Management LP, Driehaus Capital Management LLC, Federated Hermes Inc., Goldman Sachs Group Inc., New York State Common Retirement Fund, Axiom International Investors LLC DE, Calamos Advisors LLC, and EAM Investors LLC. Company insiders that have bought Vapotherm stock in the last two years include Anthony L Arnerich, Elizabeth H Weatherman, Healthcare Holding BV Gilde, James W Liken, John Landry, Joseph Army, Michael Mcqueen, Prescott General Partners Llc, and Thomas W Smith.
View insider buying and selling activity for Vapotherm.

Shares of VAPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VAPO stock can currently be purchased for approximately $28.36.

Vapotherm has a market capitalization of $725.17 million and generates $48.10 million in revenue each year. The company earns $-51,060,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Vapotherm employs 276 workers across the globe.

The official website for Vapotherm is www.vapotherm.com.

Vapotherm's mailing address is 100 DOMAIN DRIVE, EXETER NH, 03833. The company can be reached via phone at 603-658-0411 or via email at [email protected]